---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037076"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:28:29.729728+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D

## Summary
- Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.
- Estimated net proceeds of $120.2M after underwriting discounts and expenses.
- Proceeds to fund Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs; remainder for working capital.
- Underwriting led by TD Securities and BMO Capital Markets; expected close August 1, 2025.
- Cystic Fibrosis Foundation to purchase 1,818,181 shares without any underwriting discounts.

## SEC filing metadata
- accession: 0001628280-25-037076
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/0001628280-25-037076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/prme-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037076
- JSON: https://secwatch.observer/filing/0001628280-25-037076.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.